1.30

3.70% -0.05

Allarity Therapeutics Inc (ALLR)

Overview News Price History Financials Discussions Forecast Stock Split

Allarity Therapeutics Inc stock is traded at $1.30, with a volume of 160.33K. It is down -3.70% in the last 24 hours and up +15.04% over the past month. Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Previous Close:

$1.35

Open:

$1.36

24h Volume:

160.33K

Relative Volume:

0.94

Market Cap:

$20.56M

Revenue:

Net Income/Loss:

$-11.23M

P/E Ratio:

-1.636

EPS:

-0.7946

Net Cash Flow:

$-14.83M

1W Performance:

-2.99%

1M Performance:

+15.04%

6M Performance:

-10.34%

1Y Performance:

+11.11%

1-Day Range:

$1.28

$1.38

1-Week Range:

$1.28

$1.4099

52-Week Range:

$0.7687

$2.35

Allarity Therapeutics Inc Stock (ALLR) Company Profile

Name

Allarity Therapeutics Inc

Sector

Healthcare (1118)

Industry

Biotechnology (615)

Phone

401-426-4664

Address

24 SCHOOL ST., 2ND FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

2026-05-08

Latest SEC Filings

ALLR's Discussions on Twitter

Compare ALLR vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALLR Allarity Therapeutics Inc	1.30	21.67M	0	-11.23M	-14.83M	-0.7946
VRTX Vertex Pharmaceuticals Inc	424.00	109.41B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	76.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.20B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	40.31B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	33.13B	5.36B	287.73M	924.18M	2.5229

Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-28-25	Initiated	Ascendiant Capital Markets	Buy

Allarity Therapeutics Inc Stock (ALLR) Latest News

Apr 30, 2026

Allarity Therapeutics (NASDAQ: ALLR) details 2026 votes on ELOC, pay and equity plan - Stock Titan

Apr 30, 2026

Equity grant gives Allarity Therapeutics (ALLR) officer 133,333 RSUs - Stock Titan

Apr 30, 2026

Allarity Therapeutics (ALLR) CFO awarded 150,000 restricted stock units - Stock Titan

Apr 30, 2026

[ARS] Allarity Therapeutics, Inc. SEC Filing - Stock Titan

Apr 30, 2026

Apr 28, 2026

USPTO allows Allarity (NASDAQ: ALLR) stenoparib DRP patent with exclusivity to 2039 - Stock Titan

Apr 28, 2026

Apr 27, 2026

Allarity receives USPTO patent notice for stenoparib diagnostic - Investing.com UK

Apr 27, 2026

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office - Investing News Network

Apr 27, 2026

Allarity Therapeutics announces that the stenoparib drp® test has received a notice of allowance from the US Patent and Trademark Office - marketscreener.com

Apr 27, 2026

Allarity receives USPTO patent notice for stenoparib diagnostic By Investing.com - Investing.com Canada

Apr 27, 2026

Allarity patent notice puts stenoparib companion test on path to 2039 - Stock Titan

Apr 27, 2026

SEC Form 424B3 filed by Allarity Therapeutics Inc. - Quantisnow

Apr 27, 2026

255,103 Shares Registered for Resale by 3i, LP — Allarity (NASDAQ: ALLR) - Stock Titan

Apr 27, 2026

[EFFECT] Allarity Therapeutics, Inc. SEC Filing - Stock Titan

Apr 27, 2026

Apr 24, 2026

Allarity Therapeutics (NASDAQ: ALLR) updates auditor consent in S-3/A - Stock Titan

Apr 24, 2026

Apr 23, 2026

ALLR (Allarity Therapeutics Inc.) reports narrower Q3 2025 loss than expected, but shares dip slightly in today’s trading.Earnings Miss - Xã Thanh Hà

Apr 23, 2026

Apr 22, 2026

Allarity Therapeutics (NASDAQ: ALLR) highlights new stenoparib and DRP® data from AACR 2026 - Stock Titan

Apr 22, 2026

Allarity presents cancer drug data at AACR meeting By Investing.com - Investing.com India

Apr 22, 2026

Apr 21, 2026

Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer - Investing News Network

Apr 21, 2026

Allarity presents cancer drug data at AACR meeting - Investing.com

Apr 21, 2026

Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer - ChartMill

Apr 21, 2026

Apr 20, 2026

Allarity (ALLR) Stock Enterprise Value (Drifts Higher) 2026-04-20Trending Buy Opportunities - Xã Vĩnh Công

Apr 20, 2026

Apr 13, 2026

Aug Reactions: Will Allarity Therapeutics Inc stock recover after earningsPortfolio Risk Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

Earnings Miss: Can Allarity Therapeutics Inc weather a recessionCEO Change & AI Driven Stock Price Forecasts - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

[PRE 14A] Allarity Therapeutics, Inc. Preliminary Proxy Statement - Stock Titan

Apr 10, 2026

ALLR: Ascendiant Capital Maintains Buy Rating, Raises Price Targ - GuruFocus

Apr 10, 2026

Apr 02, 2026